Teva Pharmaceuticals USA, INC.
pharmaceutical company
Based in PA
AI Overview
With $1.2M in lobbying spend across 15 quarterly filings, Teva Pharmaceuticals USA, INC is a significant lobbying presence. Their lobbying covers 4 issue areas. Active from 2019 to 2022.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $235K |
| 2020 | $320K |
| 2021 | $320K |
| 2022 | $320K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy, Medicare/Medicaid, MED
Issues pertaining to pharmaceutical and healthcare markets
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act
H.R.1503, Orange Book Transparency Act
H.R.1520, Purple Book Continuity Act
H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act
H.R.2376/ S.1227, Prescription Pricing for the People Act
S.1416, Affordable Prescriptions for Patients Act
S.1895, Lower Health Care Costs Act
H.R. 1499, Protecting Consumer Access to Generic Drugs Act
Administration review of drug pricing policies
S.2543, Prescription Drug Pricing Reduction Act
S.1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act
H.R.2296, METRIC Act
Administration review of drug pricing policies
S.2543, Prescription Drug Pricing Reduction Act
S.1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act
H.R.1865, FY2020 Further Consolidated Appropriations Act
Administration review of drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act
S. 1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act
H.R. 6201, Families First Coronavirus Response Act
H.R. 748, CARES Act
Review of Administration drug pricing policies
S. 2543, Prescription Drug Pricing Reduction Act
S. 1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
Coronavirus stimulus legislation
Review of Administration drug pricing policies
Showing 8 of 11 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.